H2AX and neoplasm: Therapeutic efficacy was assessed via γ-H2AX staining—a biomarker specific for double-strand DNA breaks—revealing that 195mPt-BP induced a 4.6-fold greater fraction of γ-H2AX-positive tumor cells (1.66 ± 0.4%) compared to 195mPt-cisplatin (0.36 ± 0.1%) and an 11-fold increase over non-radioactive Pt-BP (0.15 ± 0.1%) (76).